Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryApr022024	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune Read All »	View HTML
Toggle SummaryMar052024	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune Read All »	View HTML
Toggle SummaryFeb262024	Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus ; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Read All »	View HTML
Toggle SummaryFeb282023	Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initiated in FT576 Phase 1 Study for Multiple Myeloma; Interim Clinical Data from Single-dose Cohorts Showed Objective Responses and Selective Depletion of Activated Host Immune Cells Read All »	View HTML
Toggle SummaryFeb282022	Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at ≥90 Million Cells Granted RMAT Designation for FT516 in R/R DLBCL; Read All »	View HTML
Toggle SummaryMar052019	Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Therapy in the United States $201 Million in Cash & Short-term Investments as of December 31, 2018 SAN DIEGO , March 05, 2019 (GLOBE Read All »	View HTML
Toggle SummaryMar052018	Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow All Subjects in PROTECT Phase 1 Study of ProTmune Achieve Day 100 Relapse-free Survival Clinical-scale Production of FT500 Off-the-Shelf NK Cell Cancer Immunotherapy Initiated Read All »	View HTML
Toggle SummaryMar032016	Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results ProTmune™ Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016 Data Updates for All Preclinical Adoptive Immunotherapy Programs Expected in 1H16 SAN DIEGO, Read All »	View HTML Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results 38.1 KB
Toggle SummaryMar172014	Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Phase 2 PUMA Study of PROHEMA® Initiated - Interim Data Expected in 2H14 Clinical Trial of PROHEMA ® in Lysosomal Storage Disorders to Begin in 2H14 Encouraging Clinical Data Published Highlighting the Potential of Ex Vivo T Cell Modulation SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Read All »	View HTML Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results 84.4 KB
Toggle SummaryFeb242021	Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 Clinical Activity of FT596 as Monotherapy Demonstrated in Refractory DLBCL; Partial Response Achieved, Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.